Primary regulatory

Rapamune (sirolimus) tablets: Medical Review.

FDA Center for Drug Evaluation and Research. Rapamune (sirolimus) tablets: Medical Review. NDA 21-110. 2000. Notes prior oral-solution approval on 1999-09-15.

U.S. Food and Drug AdministrationPublished 2000Accessed 2026-07-12

Open original source

Registry record

Source metadata

Publisher
U.S. Food and Drug Administration
Source type
Primary regulatory
Registry ID
research-rapa-01
Source code
RAPA-01

Source usage

Linked from 1 page

Interpretation boundary

What this record can and cannot establish

Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.